Entasis Therapeutics

OverviewSuggest Edit

Entasis Therapeutics is a pharmaceutical company developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. The Company has developed a robust clinical and pre-clinical pipeline of first- and best-in-class medicines, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae). 
TypePublic
Founded2015
HQWaltham, MA, US
Websiteentasistx.com

Latest Updates

Employees (est.) (Mar 2019)33
Job Openings8
Revenue (FY, 2019)$7 M(+40%)
Share Price (Sept 2021)$2.9(-2%)
Cybersecurity ratingAMore

Key People/Management at Entasis Therapeutics

David Meek

David Meek

Chairman
Manos Perros

Manos Perros

President and Chief Executive Officer, Director
Michael Gutch

Michael Gutch

Chief Business Officer / Chief Financial Officer
David Altarac

David Altarac

Chief Medical Officer
Heather Behanna

Heather Behanna

Director
John Mueller

John Mueller

Chief Development Officer
Show more

Entasis Therapeutics Office Locations

Entasis Therapeutics has an office in Waltham
Waltham, MA, US (HQ)
35 Gatehouse Dr
Show all (1)

Entasis Therapeutics Financials and Metrics

Entasis Therapeutics Revenue

Entasis Therapeutics's revenue was reported to be $7 m in FY, 2019
USD

Net income (Q1, 2021)

(10.7m)

EBIT (Q1, 2021)

(12.7m)

Market capitalization (8-Sept-2021)

107.1m

Closing stock price (8-Sept-2021)

2.9

Cash (31-Mar-2021)

44.9m

EV

62.7m
Entasis Therapeutics's current market capitalization is $107.1 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

5.0m7.0m

General and administrative expense

3.3m5.6m10.2m13.8m13.2m

R&D expense

15.8m25.7m33.0m40.2m41.0m

Operating expense total

19.1m31.3m43.2m53.9m54.2m
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

7.0m

General and administrative expense

1.3m2.1m3.2m3.4m3.5m3.8m3.2m3.2m3.3m

R&D expense

7.2m8.1m11.0m10.7m7.6m11.6m10.2m9.4m9.4m

Operating expense total

8.5m10.2m14.2m14.1m11.1m15.4m13.5m12.6m12.7m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

26.3m55.1m49.4m16.0m53.2m

Accounts Receivable

722.0k

Prepaid Expenses

152.0k497.0k2.0m4.6m4.2m

Current Assets

26.6m56.3m88.8m49.0m60.1m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

33.6m94.0m13.5m5.2m15.3m17.5m50.8m61.2m44.9m

Accounts Receivable

2.6m2.9m7.0m

Prepaid Expenses

1.9m2.4m2.6m3.6m4.0m2.9m2.6m3.6m2.7m

Current Assets

38.1m99.3m78.9m64.2m61.1m32.8m54.7m68.4m51.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(19.1m)(29.9m)(33.0m)(43.8m)(50.5m)

Depreciation and Amortization

177.0k194.0k164.0k142.0k141.0k

Accounts Payable

133.0k(30.0k)(644.0k)

Cash From Operating Activities

(16.0m)(27.2m)(35.8m)(44.7m)(45.4m)
Quarterly
USDQ2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(12.4m)(20.8m)(16.4m)(24.9m)(12.9m)(26.3m)(29.8m)(15.3m)(28.7m)(39.8m)(10.7m)

Depreciation and Amortization

97.0k194.0k89.0k177.0k40.0k77.0k110.0k37.0k76.0k109.0k28.0k

Accounts Payable

2.7m(632.0k)(385.0k)(154.0k)230.0k(698.0k)(226.0k)

Cash From Operating Activities

(13.5m)(21.7m)(19.2m)(27.8m)(10.6m)(26.0m)(36.7m)(13.6m)(24.6m)(37.7m)(10.1m)
USDFY, 2016

Financial Leverage

1.2 x
Show all financial metrics

Entasis Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Entasis Limited (UK)
Entasis Therapeutics Inc

Entasis Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Entasis Therapeutics Online and Social Media Presence

Embed Graph

Entasis Therapeutics News and Updates

Entasis Therapeutics to Host Expert Perspectives Webinar on Acinetobacter Infections

– Virtual Event to be Held Tuesday, August 24 at 10am Eastern Time –

Entasis Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

WALTHAM, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced members of management will participate in the Wedbush PacGrow He…

Entasis Therapeutics and Zai Lab Complete Patient Enrollment in the ATTACK Phase 3 Registrational Clinical Trial of Sulbactam-Durlobactam

            – First clinical trial to specifically study confirmed carbapenem-resistant Acinetobacter infections–            – Phase 3 top-line data readout now anticipated in early 4Q 2021 –

Entasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial Officer

– Significant commercial strategy and product launch experience –– ATTACK Phase 3 top-line data readout remains on-track for 2H 2021 –

Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens

WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the presentation of preclinical data on ETX0462, a novel, first-…

Thinking about buying stock in The GEO Group, Palantir Technologies, Entasis Therapeutics, Clean Energy Fuels, or New Oriental Education?

NEW YORK, June 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GEO, PLTR, ETTX, CLNE, and EDU. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Entasis Therapeutics Blogs

Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Content Import Thu, 09/09/2021 - 08:03 Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 9, 2021 at 8:00 AM EDT …

Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Content Import Wed, 08/11/2021 - 16:06 Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update August 11, 2021 at 4:05 PM EDT …

Entasis Therapeutics to Report Second Quarter 2021 Results and Host Conference Call August 12, 2021

Entasis Therapeutics to Report Second Quarter 2021 Results and Host Conference Call August 12, 2021 Content Import Thu, 08/05/2021 - 16:01 Entasis Therapeutics to Report Second Quarter 2021 Results and Host Conference Call August 12, 2021 August 5, 2021 at 4:01 PM EDT …

Entasis Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

– ATTACK Phase 3 topline data readout remains on track for second half of 2021 –              – Strengthened balance sheet with $20M financing – WALTHAM, Mass. , May 05, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on

Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium

WALTHAM, Mass. , Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that members of management will participate in A.G.P.’s Virtual

Entasis Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Entasis Therapeutics to Participate in Upcoming Healthcare Investor Conferences Content Import Thu, 09/10/2020 - 08:02 Entasis Therapeutics to Participate in Upcoming Healthcare Investor Conferences September 10, 2020 at 8:00 AM EDT This release is a backfill …
Show more

Entasis Therapeutics Frequently Asked Questions

  • When was Entasis Therapeutics founded?

    Entasis Therapeutics was founded in 2015.

  • Who are Entasis Therapeutics key executives?

    Entasis Therapeutics's key executives are David Meek, Manos Perros and Michael Gutch.

  • How many employees does Entasis Therapeutics have?

    Entasis Therapeutics has 33 employees.

  • Who are Entasis Therapeutics competitors?

    Competitors of Entasis Therapeutics include Alembic Pharmaceuticals, Livzon Pharmaceutical Group and Cipla.

  • Where is Entasis Therapeutics headquarters?

    Entasis Therapeutics headquarters is located at 35 Gatehouse Dr, Waltham.

  • Where are Entasis Therapeutics offices?

    Entasis Therapeutics has an office in Waltham.

  • How many offices does Entasis Therapeutics have?

    Entasis Therapeutics has 1 office.